AtaGenix Custom rMet Protein Advances Diabetes β-Cell Research

Research Background

Meteorin-like (METRNL) is an emerging secreted protein with a crucial role in safeguarding pancreatic β-cells, enhancing insulin secretion, and counteracting diabetes-associated metabolic stress. Recent studies have demonstrated that METRNL preserves β-cell identity by inhibiting β-to-α trans-differentiation, thereby slowing the progression of insulin resistance and diabetes. A landmark paper published in Diabetologia (2025, DOI: 10.1007/s00125-025-06459-7) highlighted its therapeutic potential in diabetes intervention.

Client Needs

The collaborating research team sought to investigate METRNL’s protective effects under metabolic stress. To achieve this, they required recombinant METRNL (rMet) protein of exceptionally high quality: purity above 95%, endotoxin-free, and validated for both in vivo mouse models (including high-fat diet and db/db mice) and in vitro assays such as insulin secretion, Western blotting, IHC, and ELISA. In short, the team needed a reliable, ready-to-use protein that could seamlessly support both mechanistic studies and translational research.

Technical Challenges

Developing METRNL protein was not without obstacles:

• Its tendency to misfold during recombinant expression often reduces bioactivity.
• Strict endotoxin-free requirements had to be met for in vivo safety.
• Ensuring protein stability in metabolically stressed diabetic models was critical.
• High-yield, high-purity expression systems needed to be optimized for consistent supply.

Customized Solutions

To overcome these hurdles, AtaGenix designed a tailored workflow:

• Smart Design and Expression: A HEK293 mammalian cell expression system was chosen to ensure proper folding and post-translational modifications. Codon optimization and a His-tag strategy enhanced both yield and purification efficiency.
• Robust Purification: Multi-step purification combining Ni-NTA affinity and ion-exchange chromatography delivered protein purity above 95%. Endotoxin testing (LAL assay) confirmed levels below detection limits, meeting in vivo safety standards.
• Comprehensive Validation: Identity was confirmed with METRNL-specific antibodies via Western blot, purity by SDS-PAGE, and functional concentration/activity by ELISA. Functional assays in INS-1 β-cells and mouse islets demonstrated enhanced insulin secretion and regulation of key β-cell genes (Ins1, Ins2, Pdx1).
• End-to-End Support: Beyond delivery, AtaGenix provided QC reports, application protocols, and technical guidance to ensure smooth integration into the team’s experimental pipeline.

Research Outcomes and Impact

With AtaGenix’s rMet protein, the research team successfully demonstrated improved glucose clearance and plasma insulin levels in both high-fat diet and db/db mouse models. Importantly, rMet inhibited β-to-α trans-differentiation, reinforcing β-cell identity under metabolic stress. These findings confirmed the role of METRNL–c-Jun signaling in diabetes pathophysiology and opened new avenues for developing METRNL as a therapeutic target. For the client, the project not only yielded high-impact data but also set the foundation for future translational research in diabetes therapy.

Figure 1. In vivo validation of rMet protein in diabetic mouse models. Administration of AtaGenix-produced recombinant METRNL improved glucose clearance and plasma insulin levels, confirming functional bioactivity under metabolic stress conditions.

Figure 2. METRNL protein activity analysis. Functional assays in INS-1 β-cells and mouse islets demonstrated enhanced insulin secretion and upregulation of key β-cell identity genes (Ins1, Ins2, Pdx1), confirming that the recombinant protein retained full biological activity.

This case study is based on a published research collaboration. Results may vary depending on target protein, model system, and project scope. All proprietary client information is subject to NDA.